SEC Form 4 · accession 0001193125-26-380584
Decoy Therapeutics Inc. · DCOY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan I Lieber
Director
Period of report
Aug 31, 2026
Accepted (ET)
Sep 2, 2026 · 6:32 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001615219
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 31, 2026 | A | 2,000 | $0.00 | A | 2,002 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027.
- F2Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026.